Advances and highlights in T and B cell responses to drug antigens

dc.centroFacultad de Medicinaes_ES
dc.contributor.authorFernández-Santamaría, Rubén
dc.contributor.authorAriza Veguillas, Adriana
dc.contributor.authorFernández-Duarte, Tahía Diana
dc.contributor.authorCéspedes Lagos, José Antonio
dc.contributor.authorLabella, Marina
dc.contributor.authorMayorga Mayorga, Cristobalina
dc.contributor.authorTorres-Jaén, María Josefa
dc.date.accessioned2022-05-06T10:26:51Z
dc.date.available2022-05-06T10:26:51Z
dc.date.issued2021-10-07
dc.departamentoMedicina y Dermatología
dc.description.abstractThe immunological mechanisms involved in drug hypersensitivity reactions (DHRs) are complex, and despite important advances, multiple aspects remain poorly understood. These not fully known aspects are mainly related to the factors that drive towards either a tolerant or a hypersensitivity response and specifically regarding the role of B and T cells. In this review, we focus on recent findings on this knowledge area within the last 2 years. We highlight new evidences of covalent and non-covalent interactions of drug antigen with proteins, as well as the very first characterization of naturally processed flucloxacillin-haptenated human leukocyte antigen (HLA) ligands. Moreover, we have analysed new insights into the identification of risk factors associated with the development of DHRs, such as the role of oxidative metabolism of drugs in the activation of the immune system and the discovery of new associations between DHRs and HLA variants. Finally, evidence of IgG-mediated anaphylaxis in humans and the involvement of specific subpopulations of effector cells associated with different clinical entities are also topics explored in this review. All these recent findings are relevant for the underlying pathology mechanisms and advance the field towards a more precise diagnosis, management and treatment approach for DHRs.es_ES
dc.description.sponsorshipFunding for open access charge: Universidad de Málaga / CBUA. This work has been supported by Institute of Health ‘Carlos III’ (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) (grants co-funded by European Regional Development Fund: PI15/01206, PI17/01237, PI18/00095, RETICS ARADYAL RD16/0006/0001). Andalusian Regional Ministry of Health (grants PI-0241-2016, PE-0172-2018, PI-0127-2020). AA holds a Senior Postdoctoral Contract (RH-0099-2020) from Andalusian Regional Ministry of Health (cofunded by European Social Fund (ESF): ‘Andalucía se mueve con Europa’). ML holds a ‘Rio Hortega’ contract (CM20/00210) by ISCIII of MINECO (cofunded by ESF). CM holds a ‘Nicolas Monardes’ research contract by Andalusian Regional Ministry Health (RC-0004-2021).es_ES
dc.identifier.citationFernandez-Santamaria R, Ariza A, Fernandez TD, et al. Advances and highlights in T and B cell responses to drug antigens. Allergy. 2022;77:1129– 1138. https://doi.org/10.1111/all.15126es_ES
dc.identifier.doi10.1111/all.15126
dc.identifier.urihttps://hdl.handle.net/10630/24060
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectInmunologíaes_ES
dc.subject.otherB celles_ES
dc.subject.otherBasic immunologyes_ES
dc.subject.otherDrug allergyes_ES
dc.subject.otherT celles_ES
dc.titleAdvances and highlights in T and B cell responses to drug antigenses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationec13929c-d0d4-4616-ac5f-411b50d3e75a
relation.isAuthorOfPublicationabcd4607-b47d-4018-86ad-3b5f76cbee1e
relation.isAuthorOfPublication.latestForDiscoveryec13929c-d0d4-4616-ac5f-411b50d3e75a

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Allergy - 2021 - Fernandez‐Santamaria - Advances and highlights in T and B cell responses to drug antigens (1).pdf
Size:
741.17 KB
Format:
Adobe Portable Document Format
Description:

Collections